In the world of diagnostics, we often conflate "detection" with "infection." If a test finds viral RNA or bacterial DNA, we assume the patient is sick and contagious. However, a growing body of research across SARS-CoV-2, malaria, and veterinary medicine reveals a critical "viability gap": molecular tests are exceptionally good at finding genetic blueprints, but they cannot tell if those blueprints belong to a living, replicating threat or a harmless biological "corpse."
The Sensitivity Paradox
Molecular tools like Polymerase Chain Reaction (PCR) are designed for extreme sensitivity. They amplify tiny fragments of genetic material until they are detectable. While this makes them the gold standard for early diagnosis, it creates a paradox during recovery. As David W. Eyre and Sheila Lumley observed in healthcare workers, individuals can continue to test positive for weeks after their symptoms vanish.
This happens because the body’s immune system neutralizes pathogens, but the "debris"—the RNA or DNA—persists. In Laboratory Diagnosis of SARS, Paul K.S. Chan and colleagues noted a significant discrepancy: they could detect viral RNA in samples where they could no longer isolate a live, infectious virus. The test was seeing the smoke, but the fire had already been extinguished.
Reservoirs and Residuals
The gap between detection and infectivity is often driven by where the pathogen hides. In An Asymptomatic SARS-CoV-2-Infected Infant With Persistent Fecal Viral RNA Shedding, Shen Chen documented an infant shedding viral RNA in feces for 100 days. Similarly, Martin C.W. Chan found that while influenza RNA is common in stool, the harsh acidity of the digestive tract usually inactivates the virus, leaving only non-infectious genetic remnants.
This phenomenon isn't limited to viruses. In malaria research, Bonnie Mappin and Peter W. Gething highlighted that Rapid Diagnostic Tests (RDTs) often detect lingering parasite proteins rather than active infections. This leads to a systematic overestimation of disease burden, as patients who have been successfully treated still "test positive" because the biochemical evidence of their past infection hasn't yet cleared their bloodstream.
Establishing the Ground Truth
To bridge this gap, researchers use "viability assays"—methods that prove a pathogen can actually function.
- Viral Culture: Glorijoy Shi En Tan and Lin Cui used Vero E6 cell lines to show that "re-detectable positive" COVID-19 patients were shedding non-viable fragments. If the virus cannot infect a cell in a dish, it likely cannot infect a person in the community.
- Plaque Purification: In studies of adenovirus co-infections, Gary J. Vora used physical separation to ensure that detected viruses were independent, replication-competent entities rather than passive contaminants.
- Molecular Masking: For diseases like African Swine Fever, researchers are exploring the use of Propidium Monoazide (PMA). As discussed in Prospects for the application of infectious virus detection technology, PMA can "mask" the DNA of dead viruses, allowing PCR to only amplify material from intact, infectious particles.
From Test-Based to Time-Based Policy
Understanding the viability gap has profound real-world implications. If we rely solely on the presence of genetic material, we risk unnecessary quarantines and hospital staffing shortages. Zhiyao Li and colleagues have argued for refining quarantine limits based on the actual window of live viral shedding rather than just PCR positivity.
The research suggests a shift in how we interpret diagnostic data. Instead of treating every positive result as an active threat, we must distinguish between the molecular footprint (the presence of RNA/DNA) and the biological reality (the presence of a viable, transmissible pathogen). As Manyun Yang demonstrated with Nanopore sequencing, moving toward RNA-based or metatranscriptomic approaches may eventually allow us to identify living pathogens in real-time, finally closing the gap between detection and true diagnosis.